Scott Pintoff, General Counsel and Secretary at MarketAxess Holdings Inc (MKTX), sold 100 shares of the company on June 10, 2026, reducing his holding to 11,786 shares. Over the past year, Pintoff has sold 700 shares with no purchases, aligning with a broader trend of nine insider sells and zero buys at MarketAxess. The stock, trading at $116.03, is considered significantly undervalued with a price-to-GF-Value ratio of 0.46, despite trading below the industry median P/E ratio.

John Key, a Director at Palo Alto Networks Inc (PANW), sold 7,500 shares of the company on June 12, 2026, reducing his total holdings to 12,500 shares. The transaction occurred while PANW was trading at $279.24, indicating the stock is significantly overvalued based on its GF Value of $212.71. This sale contributes to a trend of 34 insider sells against only 1 buy for PANW over the past year.

Kelly Garcia, Executive Vice President, Chief Technology & Data Officer at Domino's Pizza Inc (DPZ), sold 487 shares of the company on June 11, 2026, reducing her holdings to 9,351.818 shares. Over the past year, Garcia has sold a total of 6,333 shares with no purchases, contributing to 11 insider sells and 0 insider buys for the company. Domino's Pizza Inc's stock is currently trading at $311.74, with a price-to-GF-Value ratio of 0.65, suggesting it is significantly undervalued according to GuruFocus's intrinsic value estimate.

TKO Group Holdings director Bradley A. Keywell engaged in routine equity compensation, exercising restricted stock units (RSUs) for 1,237 shares of Class A common stock and receiving a new grant of 1,123 RSUs. Following these transactions, his direct holdings increased to 4,125 Class A shares. The RSUs vested on June 10, 2026, the date of the company's annual stockholder meeting, with the new grant set to vest at the next annual meeting.

TKO Group Holdings director Carrie Wheeler reported equity compensation activity, exercising 1,237 restricted stock units (RSUs) to acquire Class A common stock, increasing her direct holdings to 7,836 shares. She also received a new grant of 1,123 RSUs. Both the exercised and newly granted RSUs have specific vesting dates tied to the company's annual stockholder meetings.

TKO Group Holdings director Sonya E. Medina increased her equity stake by exercising 1,237 restricted stock units (RSUs) into Class A common stock and receiving a new grant of 1,123 RSUs. These transactions are part of her routine equity compensation, bringing her direct holdings to 4,937 shares. The newly granted RSUs are set to vest on the date of the company's next annual stockholder meeting.

Traws Pharma (NASDAQ: TRAW) has deferred its planned Phase 2a human influenza challenge study for tivoxavir marboxil (TXM) following a negative review from the UK's MHRA, delaying clinical evaluation of its lead antiviral candidate. Despite this setback, the company maintains its commitment to influenza antivirals, citing TXM's efficacy in animal models and a cash runway extending to Q1 2027. Traws Pharma is actively advancing backup influenza candidates designed to avoid regulatory concerns while preserving similar antiviral and pharmacokinetic characteristics.

Traws Pharma announced that its planned Phase 2a human influenza challenge study for tivoxavir marboxil (TXM) has been deferred due to a negative review from the UK's MHRA. Despite this setback, the company's Chief Science Officer noted TXM's potential for emergency use in bird flu outbreaks, and the company is advancing alternative influenza antiviral candidates. Traws Pharma remains committed to developing long-acting influenza antivirals, extending its cash runway to Q1 2027 to support these efforts.

Traws Pharma announced a regulatory setback for its influenza program, deferring a planned Phase 2a human trial of tivoxavir marboxil (TXM) due to a negative review by the UK MHRA. Despite this, the company emphasized TXM's efficacy in animal models and its commitment to developing long-acting influenza antivirals, advancing backup candidates. Traws Pharma also confirmed a cash runway extending into Q1 2027 to support ongoing development.

Arista Networks (NYSE: ANET) stock rose over 4% on Friday following a bullish report from Morgan Stanley analyst Meta Marshall, who raised her price target to $190 from $180 while maintaining an "overweight" rating. Marshall believes Arista Networks is well-positioned to benefit as artificial intelligence (AI) implementations move into the inference stage, requiring next-generation equipment and increased processing power. The company is seen as a high-value supplier in cloud networking, poised to capitalize on the scaling of AI technologies.